Truqap 160 mg Tablets: Uses, Side Effects and Overview
Quick summary: Truqap 160 mg film-coated tablets contain capivasertib, an oral targeted cancer medicine used in specific cases of advanced breast cancer. It is typically discussed as part of combination treatment and requires close...
This content is for educational purposes only and does not replace medical advice, diagnosis or treatment from a qualified healthcare professional.
Quick summary: Truqap 160 mg film-coated tablets contain capivasertib, an oral targeted cancer medicine used in specific cases of advanced breast cancer. It is typically discussed as part of combination treatment and requires close medical monitoring.
This overview explains what Truqap is, what it is used for, possible side effects, and key points to verify with a doctor or pharmacist.
Medical disclaimer: This article is for general information only and does not replace advice from an oncologist, pharmacist, or the official patient leaflet. Cancer treatment decisions depend on the individual diagnosis, test results, and treatment history.
What is Truqap?
Truqap is an oral medicine containing capivasertib. It is described as an AKT kinase inhibitor, meaning it targets a pathway involved in cancer cell growth and survival.
In the original content, Truqap is presented as a film-coated tablet used in specific breast cancer settings, especially when combined with other therapies such as fulvestrant. It is also mentioned in relation to patients with PIK3CA mutations.
What is Truqap used for?
Truqap is described as being used for advanced or metastatic breast cancer, particularly in cases that are ER-positive and HER2-negative.
The original content also notes that it may be used alongside other treatments, including fulvestrant and, in premenopausal women, an LHRH agonist. The exact treatment plan should always be confirmed by the treating oncology team.
- Advanced or metastatic breast cancer
- ER-positive, HER2-negative disease
- Combination use with fulvestrant
- Use in patients with PIK3CA mutations, as described in the source content
How does Truqap work?
Truqap works by blocking the AKT pathway. This pathway is involved in signals that can support cancer cell growth and survival.
By inhibiting AKT, Truqap is intended to interfere with those signals and help slow cancer progression. This is why it is considered a targeted therapy rather than traditional chemotherapy.
Is Truqap chemotherapy?
No. Based on the original content, Truqap is a targeted therapy, not standard chemotherapy.
That distinction matters because targeted therapies act on specific molecular pathways, while chemotherapy generally affects rapidly dividing cells more broadly.
What are the side effects of Truqap?
The original content lists several possible side effects. Commonly mentioned effects include:
- Diarrhea
- Nausea
- Rash or skin eruptions
- Hyperglycemia, or high blood sugar
- Fatigue
More serious reactions were also mentioned, including severe allergic reactions and DRESS syndrome, which can affect multiple organs.
People with diabetes or other medical conditions may need especially close monitoring, but treatment decisions and monitoring plans should be made by the healthcare team.
What should patients verify before taking Truqap?
If Truqap is being considered, the most useful next step is to confirm the details with the oncology team or pharmacist. The original content suggests checking:
- Whether the cancer type matches the intended use
- Whether the treatment is meant to be combined with fulvestrant
- Whether an LHRH agonist is part of the plan for premenopausal women
- Whether any genetic testing results, such as PIK3CA status, are relevant
- What monitoring is needed for blood sugar and skin reactions
Truqap vs Piqray
The original content compares Truqap with Piqray (alpelisib). Both are targeted breast cancer therapies, but they are not the same.
Truqap is described as an AKT inhibitor, while Piqray is described as a PI3K inhibitor. They may also differ in eligibility, side effects, and how they are used in treatment plans.
| Medicine | Main target | Source content summary |
|---|---|---|
| Truqap | AKT | Targeted therapy used in specific advanced breast cancer settings |
| Piqray | PI3K | Another targeted breast cancer therapy with a different mechanism |
What is known about Truqap reviews?
The original content says reviews and clinical feedback have been generally positive, especially regarding progression-free survival in selected patients. It also notes that side effects can be manageable with monitoring.
For readers, the most reliable sources of information are the official prescribing information, oncology guidance, and the treating specialist’s explanation of how the medicine fits the individual case.
How much does Truqap cost?
The original content states that cost can vary depending on location, healthcare provider, and insurance coverage. It also mentions that financial assistance may sometimes be available.
Because pricing changes by country and system, the most practical step is to check with the dispensing pharmacy, insurer, or hospital team for current information.
Frequently asked questions
▸ How does Truqap work?
Truqap works by inhibiting AKT, a protein involved in cancer cell growth and survival. This makes it a targeted therapy.
▸ What cancer is Truqap used for?
The source content describes Truqap as being used for advanced or metastatic breast cancer, especially ER-positive and HER2-negative disease.
▸ Is Truqap the same as chemotherapy?
No. The original content describes Truqap as a targeted therapy rather than traditional chemotherapy.
▸ What side effects are mentioned for Truqap?
Diarrhea, nausea, rash, high blood sugar, and fatigue are listed in the source content. Serious reactions were also mentioned.
▸ Why is blood sugar monitoring important?
The source content mentions hyperglycemia as a possible side effect, so blood sugar monitoring may be important during treatment.
▸ Where can I confirm the official use of Truqap?
Check the official patient leaflet, prescribing information, or ask an oncologist or pharmacist for guidance based on the specific treatment plan.
Safety reminder: If you notice severe rash, breathing problems, signs of an allergic reaction, very high blood sugar symptoms, or any rapidly worsening symptom, seek urgent medical advice. Do not make treatment changes without speaking to the healthcare team.
Medical disclaimer
This content is for educational purposes only. It should not be used as a substitute for professional medical advice, diagnosis or treatment. Always ask a doctor, pharmacist or qualified healthcare professional before starting, stopping or changing any medicine.
Sources and verification
The following sources or official references are listed to support verification of the medicine information discussed in this article.
- European Medicines Agency: Truqap overview
- Official Truqap prescribing information / patient leaflet
- Cancer Research UK: targeted cancer drugs
- National Cancer Institute: targeted cancer therapies
To improve this article with specific references, add a custom field named _aio_sources in the post editor and write one source per line using: Source title|Source URL.
Medicine information can change and may vary depending on country, product formulation, patient history and professional guidance. Always check official medicine information and ask a healthcare professional for personal medical questions.